HEPHAISTOS-Pharma reports positive safety and efficacy preclinical data for HEPHA440 at ESMO 2026
October 28, 2026

ESMO 2026, Madrid, 23–27 October 2026 – HEPHAISTOS-Pharma presented new preclinical results (poster 4729eP) for HEPHA440, a 3rd generation TLR4 agonist rationally designed for safe systemic delivery in human targeting myeloid cells to reverse immunosuppression in tumours.
Across mouse models of triple-negative breast cancer, B-cell lymphoma and colorectal cancer, HEPHA440 showed antitumour activity both as a single agent and in combination, with complete regression rates up to 75%.
To solve the therapeutic index issue of previous generations of TLR4 agonist, HEPHA440 preferentially drives TLR4’s TRIF pathway (Type 1 cytokines and interferon) while limiting the MyD88 pathway (Pro-inflammatory cytokines and toxicity) – a profile confirmed in human blood.
In the preclinical tox model, HEPHA440 was well tolerated up to 2,200 µg/kg with signs of immune activation (x1000 higher than previous generations). Ex vivo human liver biopsies showed no impairment of liver function, in contrast to earlier-generation TLR4 agonists. The data support moving into IND-enabling studies.
Work carried out with CRCL (INSERM/CNRS, Lyon), the Lyon Hepatology Institute and Hospices Civils de Lyon, with support from ANR (France 2030) and the EIC Accelerator programme.